Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activities
Growth Metrics
Income Statement
Others
Ratios

Acro Biomedical (ACBM) Net Cash Flow (2016 - 2025)

Acro Biomedical has reported Net Cash Flow over the past 10 years, most recently at -$225.0 for Q4 2025.

  • Quarterly results put Net Cash Flow at -$225.0 for Q4 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was $3622.0 (up 3522.0% YoY), and the annual figure for FY2025 was $3622.0, up 3522.0%.
  • Net Cash Flow for Q4 2025 was -$225.0 at Acro Biomedical, down from $4297.0 in the prior quarter.
  • Over the last five years, Net Cash Flow for ACBM hit a ceiling of $262420.0 in Q1 2022 and a floor of -$345561.0 in Q2 2022.
  • Median Net Cash Flow over the past 5 years was -$225.0 (2024), compared with a mean of -$701.25.
  • Biggest five-year swings in Net Cash Flow: crashed 26936.0% in 2021 and later soared 4108.15% in 2022.
  • Acro Biomedical's Net Cash Flow stood at -$59415.0 in 2021, then surged by 82.6% to -$10336.0 in 2022, then skyrocketed by 71.99% to -$2895.0 in 2023, then surged by 92.23% to -$225.0 in 2024, then changed by 0.0% to -$225.0 in 2025.
  • The last three reported values for Net Cash Flow were -$225.0 (Q4 2025), $4297.0 (Q3 2025), and -$225.0 (Q2 2025) per Business Quant data.